바로가기메뉴

본문 바로가기 주메뉴 바로가기

ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
 

logo

메뉴

Recurrence - Related Factors of Medication Related Osteonecrosis of the Jaw (MRONJ) ; a Retrospective study

Abstract

Duration of administration of related medications, presence of bacterial infections in necrotic areas, and methods of treat ment have been suggested as factors related to the recurrence of MRONJ. The purpose of this study was to investigate recur rence risk factors in patients who had undergone surgical treatment. The recurrence rate was statistically significant when the teeth affected by alveolar bone necrosis were removed together. When comparing patients who received post-operative antibiotic treatment, recurrence was significantly reduced. Comprehensive surgical approaches, including the extraction of adjacent teeth during surgery, and appropriate post-operative antibiotic therapy can be effective strategies for reducing the recurrence rate of MRONJ.

keywords
MRONJ, Bisphosphonate, Recurrence, Drug-holiday

참고문헌

1.

1. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 2014;72:1938.

2.

2. Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY. Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab. 2015;22:151–2.

3.

3. Miksad RA, Lai KC, Dodson TB et al. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist. 2011;16(1):121–32.

4.

4. Tsao C, Darby I, Ebeling PR, Walsh K, O'Brien-Simpson N, Reynolds E, et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 2013;71:1360-6.

5.

5. McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis 2018;24:527-36.

6.

6. Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33surgical cases. J Oral Maxillofac Surg 2009;67:943-50.

7.

7. Scoletta M, Arduino PG, Dalmasso P, Broccoletti R, Mozzati M. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:46-53.

8.

8. Mücke T, Koschinski J, Deppe H, Wagenpfeil S, Pautke C, Mitchell DA, et al. Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J Cancer Res Clin Oncol 2011;137:907-13.

9.

9. Klingelhöffer C, Zeman F, Meier J, Reichert TE, Ettl T. Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws. J Craniomaxillofac Surg 2016;44:1694-9.

10.

10. Kim HY, Lee SJ, Kim SM, Myoung H, Hwang SJ, Choi JY, Lee JH, Choung PH, Kim MJ, Seo BM. Extensive Surgical Procedures Result in Better Treatment Outcomes for Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Osteoporosis. J Oral Maxillofac Surg. 2017;75:1404-13.

11.

11. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010;136:1117–24.

12.

12. Markenson JA. Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid-arthritis. Semin Arthritis Rheum 1991;21:4–12.

13.

13. Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg 2009;67:943-50.

14.

14. Baqain ZH, Sawair FA, Tamimi Z, Bsoul N, Al Edwan G, Almasad JK, et al. Osteonecrosis of jawsrelated to intravenous bisphosphonates: the experience of a Jordanian teaching hospital. Ann R Coll Surg Engl 2010;92:489–94.

15.

15. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009;27:5356–62.

16.

16. Park W, Kim NK, Kim MY, Rhee YM, Kim HJ. Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases. Osteoporos Int 2010;21:527–33.

17.

17. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23: 8580–7.

18.

18. Johnson TE. Recent results: biomarkers of aging. Exp Gerontol 2006;41:1243–6.

19.

19. Misawa Y, Kageyama T, Moriyama K, Kurihara S, Yagasaki H, Deguchi T, et al. Effect of age on alveolar bone turnover adjacent to maxillary molar roots in male rats: a histomorphometric study. Arch Oral Biol 2007;52:44–50.

20.

20. Semba I, Funakoshi K, Kitano M. Histomorphometric analysis of age changes in the human inferior alveolar artery. Arch Oral Biol 2001;46:13–21.

21.

21. Kulikov VY, Fridman YM, Fomin AN. Role of oxidative stress in mechanisms of premature aging in shift labor workers. Alaska Med 2007;49(2 Suppl):81–4.

logo